Get the Daily Brief
Latest Biotech News
RAS-targeted pancreatic cancer gains clinical validation
Revolution Medicines reported positive Phase III results for daraxonrasib (RMC-6236), an orally administered RAS-targeting therapy in metastatic pancreatic ductal adenocarcinoma. In the RASolute...
Immune-mediated disease startup launch with BMS-inlicensed portfolio
Beeline Medicines launched with a five-program portfolio in-licensed from Bristol Myers Squibb and backed by a $300 million Series A led by Bain Capital. The company’s lead asset, afimetoran, is a...
Gene therapy commercialization reset in inherited eye disease
MeiraGTx agreed to buy back a failed eye gene therapy from Johnson & Johnson for $25 million upfront, following the therapy’s Phase 3 setback in X-linked retinitis pigmentosa. The transaction...
Nephrology diagnostics and blood donor infectious disease screening
Grifols won FDA approval for its automated malaria risk screening assay used with the Procleix Panther system. The Procleix Plasmodium Assay is a nucleic acid test for Plasmodium species...
Microbial detection and antimicrobial resistance surveillance tools
Takara Bio and Resistomap expanded their partnership to develop high-throughput antimicrobial resistance surveillance products from environmental samples. Their SmartChip Biosecurity Platform...
Molecular diagnostics workflow automation and standardization
Invivoscribe launched PrepQuant, an extraction-free sample preparation system designed to standardize pre-analytical workflows for molecular testing. The platform integrates nucleic acid...
AACR MRD detection advances and ctDNA sensitivity benchmarking
Ultima Genomics’ ppmSeq platform delivered early TRACERx MRD performance data at AACR, highlighting ultra-sensitive ctDNA detection at low single-digit parts per million in plasma samples. The...
Bioelectronics sensing with microbial co-cultures
Rice University researchers unveiled electroactive co-culture sensing (e-COSENS), a modular bioelectrical sensor system designed to convert chemical signals into electricity. The technology uses...
Takara Bio and Resistomap expand high-throughput AMR surveillance platform
Takara Bio and Resistomap said they are strengthening their partnership to deliver a high-throughput antimicrobial resistance (AMR) surveillance workflow built for environmental sampling. The...
Revolution Medicines advances RAS inhibitor daraxonrasib after Phase 3 pancreatic cancer win
Revolution Medicines’ RAS-targeting daraxonrasib moved closer to a pivotal oncology milestone after Phase 3 results in metastatic pancreatic ductal adenocarcinoma. The company reported that...
Kailera’s record $625M IPO funds obesity pipeline
Kailera Therapeutics priced a $625 million initial public offering, marking one of the largest biotech IPOs on record and positioning the company to fund its obesity pipeline. The offering capital...
Neomorph lands $100M Series B for ARNT molecular glue degrader in ccRCC
Neomorph secured a $100 million Series B to advance its oral molecular glue degrader NEO-811 through clinical development. The financing, led by Deerfield Management with participation from...
AACR MRD data highlight ppmSeq ultra-sensitive ctDNA detection approach
Ultima Genomics presented early TRACERx minimal residual disease (MRD) results at AACR emphasizing ppmSeq’s ultra-sensitive circulating tumor DNA (ctDNA) detection. The company described data from...
Roche to buy Saga Diagnostics to expand Foundation Medicine’s MRD toolkit
Roche will acquire Saga Diagnostics via its Foundation Medicine unit in a deal valued at up to $595 million to expand cancer MRD testing. Foundation Medicine says the transaction will bring Saga’s...
Storm Therapeutics raises $56M Series C to fund STC-15 Phase 2 sarcoma trial
Storm Therapeutics closed a $56 million Series C financing to support Phase II development of STC-15, an RNA modification targeting program in sarcoma. The company said it has already treated the...
FDA priority review granted for Merck-Daiichi B7-H3 ADC ifinatamab deruxtecan
The FDA granted priority review to Daiichi Sankyo and Merck’s ifinatamab deruxtecan B7-H3 antibody-drug conjugate. The agency’s decision applies to a BLA seeking treatment for patients with...
Lilly reports positive cardiovascular safety and efficacy in Phase 3 for oral obesity pill Foundayo (orforglipron)
Eli Lilly reported positive Phase 3 results for Foundayo (orforglipron) in a cardiovascular outcomes trial in adults with type 2 diabetes and obesity or overweight. The company said the study met...
Grifols wins FDA approval for Procleix malaria risk screening assay
Grifols said the FDA approved its automated Procleix Plasmodium assay used with the Procleix Panther system to screen blood donors for malaria risk. The nucleic-acid-based test is intended to...
Obesity drugs expand amid FDA safety scrutiny
Eli Lilly’s oral obesity drug Foundayo (orforglipron) cleared an important cardiovascular safety milestone in people with diabetes, meeting the main goal of non-inferiority to insulin glargine for...
Biotech IPO funding benchmark rises with Kailera’s upsized deal
Kailera Therapeutics priced a $625 million offering, a potential benchmark for biotech IPOs, to fund its obesity pipeline. The company’s larger-than-expected raise underscores investor appetite...